We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$7.1B
AUM Growth
-$1.16B
Cap. Flow
-$291M
Cap. Flow %
-4.1%
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
3
MDT icon
Medtronic
MDT
+$115M
4
DXCM icon
DexCom
DXCM
+$83.5M
5
LIVN icon
LivaNova
LIVN
+$79.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$149M
2
GILD icon
Gilead Sciences
GILD
+$133M
3
ONEM
1Life Healthcare
ONEM
+$129M
4
BEAM icon
Beam Therapeutics
BEAM
+$119M
5
SNY icon
Sanofi
SNY
+$96.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.83%
3 Consumer Staples 0.3%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
101
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-265,736
Closed -$33.3M
GWPH
102
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-815,681
Closed -$94.1M
PAND
103
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-1,398,705
Closed -$20.8M
EIDX
104
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-452,295
Closed -$59.5M
1 2 3 4
5

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2021 Portfolio in Review

As of Q1 2021, Redmile Group held 104 positions worth $7.1B, down 14% from $8.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $291M in Q1 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was AbbVie, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Seagen Inc. Common Stock worth $130M.

  • Redmile Group's largest Q1 2021 buy was Seagen Inc. Common Stock: 937,045 shares worth $130M.
  • Redmile Group added most to Fate Therapeutics in Q1 2021, an estimated $31.4M increase.
  • Redmile Group's biggest Q1 2021 reduction was 1Life Healthcare, cutting an estimated $129M.
  • Redmile Group fully exited AbbVie in Q1 2021, selling an estimated $149M.
  • Redmile Group's ten largest holdings make up 42% of its $7.1B portfolio in Q1 2021.
  • Redmile Group opened 17 new positions and closed 18 in Q1 2021.
  • Redmile Group's portfolio value fell 14% quarter-over-quarter to $7.1B.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.